avatrombopag (Doptelet)

following a full submission assessed under the orphan equivalent process:

avatrombopag (Doptelet®) is accepted for restricted use within NHSScotland.

Indication under review: Treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (e.g. corticosteroids or immunoglobulins).

SMC restriction: to use in patients with severe symptomatic ITP or a high risk of bleeding.

In a phase III study, avatrombopag was more effective than placebo in raising and maintaining platelet counts at (or above) a minimum target level in previously-treated patients with ITP.

This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.

This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.